Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Ropivacaine on Hyperalgesia and Flare Reaction
NCT00900913Phase 4Completed
- Sponsor
- University of Zurich
- Start
- Jan 2010
- Primary completion
- May 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4 trial of ropivacaine hydrochloride liposomal suspension injection in pain, sponsored by University of Zurich. Primary endpoint: Area of flare reaction, area of primary and secondary hyperalgesia at 1 year. Started Jan 2010; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
pain
Beyond the preview
Go deeper on NCT00900913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900913.